Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan PK in Hepatic Impairment
NCT03092999Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2017
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of vilaprisan in uterine leiomyoma (3 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve in plasma from zero to infinity (unbound) at 20 days and Maximum observed (unbound) drug concentration at 20 days. Started Mar 2017; status: completed.
02
Drugs
vilaprisan
03
Conditions
uterine leiomyoma
Beyond the preview
Go deeper on NCT03092999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03092999.